Study Finds Over 100 Value-Based Contracts
(2/13, Steve Usdin, BioCentury) reports “Despite legal barriers and practical obstacles, over 100 value-based contracts were negotiated between drug manufacturers and payers from 2014 to 2017, according to a study conducted by researchers at Duke University's Robert J. Margolis Center for Health Policy and the National Pharmaceutical Council...The study describes value-based arrangements as including outcomes- and performance-based contracts, as well as risk-sharing agreements that ‘link coverage, reimbursement, or payment for a product to a prespecified clinical or financial/utilization outcome or set of outcomes.’ It found that the most common outcome measures used were drug utilization and laboratory test values. The most common incentives were larger rebates to payers.” Full
How Utilizing Data Can Impact Health Costs, Improve Employee Health
(2/13, Nick Otto, Employee Benefit News) reports “...The key is looking beyond the silo of clinical effectiveness, added [Wayne Burton, former chief medical officer at American Express], to how different treatment options impact employee health and productivity. Burton noted that there are two key questions being asked when using evidence-based data: What is the effectiveness, and what is the cost offset? ‘The [treatment] cost might be high, but the price of in-patients [to the ER] dramatically dropped,’ he said. That's the importance of translating comparative effectiveness research.” Full
Data As Currency: The Value of Longitudinal Data for Pharma
(2/13, William T. Sander, PharmExec) reports “...In its December statement, the FDA recognized the value that RWD and RWE can have on such postmarketing studies...In addition, the FDA says it is also using RWD and RWE as part of the information it takes into consideration when evaluating new drug applications from pharma companies. ‘We currently have new drug applications under review where RWD and RWE are helping to inform our ongoing evaluation as one component of the total complement of information that we're evaluating,’ the organization says.” Full
FDA Approved Record Number of Personalized Medicines in 2018: Report
(2/13, Jacqueline Renfrow, Fierce Healthcare) reports “...The Personalized Medicine at FDA: A Progress & Outlook Report gives credit to the FDA for accelerating the trend of patients and payers embracing personalized medicine. In fact, personalized medicines have made up 20% of FDA approvals over the last five years, with that number jumping to 40% in 2018. Specifically, 25 of the 59 new molecular entities that the FDA approved in 2018 were personalized medicines.
Tackling Adherence Is "Only Sustainable Path to Profit"
(2/14, Amanda Barrell, PharmaPhorum) comments “...Twenty-one of the world's largest pharmaceutical companies could increase revenue and earnings per share simply by modestly boosting adherence rates. Sanofi, for example, could increase revenue by up to 12% and EPS by up to 20% between 2020 and 2026. Novo Nordisk could experience up to 29% greater revenue and 45% higher EPS in the same period...The report – The Pharmaceutical Triple Aim: Higher Medication Adherence Increases Revenue and EPS for Pharma, Improves Patient Outcomes and Lowers Healthcare Costs – was published in January, but the issue is far from new, and this latest analysis builds on a Credit Suisse investors' note from March 2018.” Full
How Machine Learning and Artificial Intelligence Might Influence Social Determinants of Health
(2/14, Emily Willingham, Association of Health Care Journalists: Covering Health) comments “...The Patient-Centered Outcomes Research Institute has devoted part of its website to addressing crucial issues in telehealth and the potential upsides and downsides. What the site does not yet dig into is how artificial intelligence will play into the delivery of telehealth, especially to under-resourced populations. That's in part because machine learning and AI are just now touching the realm of possibility when it comes to distance diagnostics.” Full
Life after Cancer: More Survivors Living Longer, Facing New Health Challenges
(2/14, Kim Painter, USA Today) reports “...‘The number of cancer survivors continues to grow, yet high-quality, coordinated survivorship care is still infrequent,’ experts from the National Academies of Sciences, Engineering, and Medicine said in a recent follow-up report...‘Strides have been made, but there's also been an acceleration in the demand,’ says Neeraj Arora, associate director for science at the nonprofit Patient-Centered Outcomes Research Institute. Arora, a 25-year survivor of non-Hodgkin lymphoma, helped write the report.” Full
UK: NICE Provides First Scientific Advice on Patient Preference Study Design
(2/14, Anna Smith, PharmaTimes) reports “...NICE anticipates that its advice will guide early evidence generation, helping to transform study design and improve the quality of current processes, with aim to support the development of new products to treat COPD patients. Jeanette Kusel, Director of NICE Scientific Advice said: ‘We are delighted to be able to shape our offering to suit the requirements of Novartis by offering advice and guidance on their patient preference study, which should help it to generate the data required to help future products meet the needs of COPD patients.’” Full
UK: Novartis First to Benefit from NICE Advice on ‘Patient Preference' (2/14, Andrew McConaghie, PMLiVE) reports “...Nigel Cook, Head of Decision Support & Insights, Global Patient Access at Novartis said: ‘The scientific advice provided by NICE, together with the patient representative and other external experts, has been very valuable to Novartis; both in endorsing the approach to gathering early patient preference data to inform evidence generation plans, and in regard to valuable input received to improve the design of the COPD patient preference study.’” Full
Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger
(2/13, Ian Haydock, Pink Sheet) reports “...Japan is taking new steps to expand what has so far been a pilot-scale cost-effectiveness assessment scheme for drugs and medical devices, a move that may lead to price adjustments for selected products, potentially including some already marketed drugs...The trial CEA scheme has so far led to 13 products (including seven devices) being designated for cost-effectiveness assessment, resulting in the repricing of two products in April 2018 as part of the wider regular biennial drug price revision in Japan at that time.” Paid Subscription Required
TARGET PharmaSolutions® Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions
(2/13, TARGET PharmaSolutions, Inc. Press Release) “...The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions, initially focusing on patients with atopic dermatitis (AD/eczema). TARGET-DERM's first participant enrolled on January 25, 2019. The trial will enroll up to 15,000 participants, including adult and pediatric patients, at up to 100 sites in the United States, Canada and Europe. TARGET-DERM will eventually include the skin conditions hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).” Full
Time-Dependent Biases in Observational Studies of Comparative Effectiveness Research in Rheumatology. A Methodological Review
Iudici M, et al.
February 12, 2019, Annals of the Rheumatic Diseases
Economic Evaluation of Sunitinib Versus Pazopanib and Best Supportive Care for the Treatment of Metastatic Renal Cell Carcinoma in Chile: Cost-Effectiveness Analysis and a Mixed Treatment Comparison
Vargas C, et al.
February 13, 2019, Expert Review of PharmacoEconomics and Outcomes Research
Systematic Reviews of Health Economic Evaluations: A Structured Analysis of Characteristics and Methods Applied
Miriam Luhnen, et al.
February 13, 2019, Research Synthesis Methods
The Value and Consequences of Using Public Health Technology Assessments for Private Payer Decision-Making in Canada: One Size Does Not Fit All
Pericleous L, et al.
February 13, 2019, Journal of Medical Economics
Personalized Medicine at FDA: A Progress & Outlook Report
Personalized Medicine Coalition
Health Affairs Briefing: Patients As Consumers
March 5, 2019
9:00AM - 12:30PM EST
National Press Club